281 related articles for article (PubMed ID: 37522121)
1. Pheochromocytoma/paraganglioma-associated cardiomyopathy.
Szatko A; Glinicki P; Gietka-Czernel M
Front Endocrinol (Lausanne); 2023; 14():1204851. PubMed ID: 37522121
[TBL] [Abstract][Full Text] [Related]
2. TAKOTSUBO-LIKE CARDIOMYOPATHY IN A LARGE COHORT OF PATIENTS WITH PHEOCHROMOCYTOMA AND PARAGANGLIOMA.
Gagnon N; Mansour S; Bitton Y; Bourdeau I
Endocr Pract; 2017 Oct; 23(10):1178-1192. PubMed ID: 28704094
[TBL] [Abstract][Full Text] [Related]
3. Acute catecholamine cardiomyopathy in patients with phaeochromocytoma or functional paraganglioma.
Giavarini A; Chedid A; Bobrie G; Plouin PF; Hagège A; Amar L
Heart; 2013 Oct; 99(19):1438-44. PubMed ID: 23837998
[TBL] [Abstract][Full Text] [Related]
4. Pheochromocytoma- and paraganglioma-triggered Takotsubo syndrome.
Y-Hassan S; Falhammar H
Endocrine; 2019 Sep; 65(3):483-493. PubMed ID: 31399912
[TBL] [Abstract][Full Text] [Related]
5. Catecholamine-induced cardiomyopathy: an endocrinologist's perspective.
Kumar A; Pappachan JM; Fernandez CJ
Rev Cardiovasc Med; 2021 Dec; 22(4):1215-1228. PubMed ID: 34957765
[TBL] [Abstract][Full Text] [Related]
6. Acute and Chronic Pheochromocytoma-Induced Cardiomyopathies: Different Prognoses?: A Systematic Analytical Review.
Batisse-Lignier M; Pereira B; Motreff P; Pierrard R; Burnot C; Vorilhon C; Maqdasy S; Roche B; Desbiez F; Clerfond G; Citron B; Lusson JR; Tauveron I; Eschalier R
Medicine (Baltimore); 2015 Dec; 94(50):e2198. PubMed ID: 26683930
[TBL] [Abstract][Full Text] [Related]
7. Pheochromocytoma as a reversible cause of cardiomyopathy: Analysis and review of the literature.
Zhang R; Gupta D; Albert SG
Int J Cardiol; 2017 Dec; 249():319-323. PubMed ID: 29121733
[TBL] [Abstract][Full Text] [Related]
8. Predictive Factors for Catecholamine-Induced Cardiomyopathy in Patients with Pheochromocytoma and Paraganglioma.
Wang Y; Yu X; Huang Y
Front Endocrinol (Lausanne); 2022; 13():853878. PubMed ID: 35355563
[TBL] [Abstract][Full Text] [Related]
9. Giant Paraganglioma Complicated With Catecholamine Crisis and Catecholamine Cardiomyopathy: A Case Report and Review of the Literature.
Ma X; Chen Z; Xia P; Zhang C; Yan K; Fan Y; Wang Y; Ti Y; Bu P
Front Endocrinol (Lausanne); 2021; 12():790080. PubMed ID: 35185782
[TBL] [Abstract][Full Text] [Related]
10. Catecholamine-induced cardiomyopathy.
Kassim TA; Clarke DD; Mai VQ; Clyde PW; Mohamed Shakir KM
Endocr Pract; 2008 Dec; 14(9):1137-49. PubMed ID: 19158054
[TBL] [Abstract][Full Text] [Related]
11. Genetic biomarkers of life-threatening pheochromocytoma-induced cardiomyopathy.
Amar J; Brunel J; Cardot Bauters C; Jacques V; Delmas C; Odou MF; Savagner F
Endocr Relat Cancer; 2022 Apr; 29(5):267-272. PubMed ID: 35258481
[TBL] [Abstract][Full Text] [Related]
12. Catecholamine-induced cardiomyopathy improvement after para-aortic paraganglioma resection: a case report.
Ranjbar M; Amin A; Totonchi Z; Ghaemmaghami Z; Jalilian Z; Hesami M; Givtaj N; Jadbabaei AN; Divanbeigi I; Mazloomfard MM
ESC Heart Fail; 2022 Feb; 9(1):213-218. PubMed ID: 34967117
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular Complications in Pheochromocytoma and Paraganglioma: Does Phenotype Matter?
Petrák O; Krátká Z; Holaj R; Zítek M; Nguyen Nikrýnová T; Klímová J; Kološová B; Waldauf P; Michalský D; Novák K; Markvartová A; Zlatohlávek L; Grus T; Dušková J; Widimský J; Zelinka T
Hypertension; 2024 Mar; 81(3):595-603. PubMed ID: 38152977
[TBL] [Abstract][Full Text] [Related]
14. Risk of complications after core needle biopsy in pheochromocytoma/paraganglioma.
Zhang L; Åkerström T; Mollazadegan K; Beuschlein F; Pacak K; Skogseid B; Crona J
Endocr Relat Cancer; 2023 Jul; 30(7):. PubMed ID: 37185155
[TBL] [Abstract][Full Text] [Related]
15. A rare cause of cardiogenic shock: catecholamine cardiomyopathy of pheochromocytoma.
Imperadore F; Azzolini M; Piscioli F; Pusiol T; Capitanio A; Vergara G
Ital Heart J; 2002 Jun; 3(6):375-8. PubMed ID: 12116803
[TBL] [Abstract][Full Text] [Related]
16. Risk Factors for Cardiac Complications in Patients With Pheochromocytoma and Paraganglioma: A Retrospective Single-Center Study.
Zhao L; Meng X; Mei Q; Fan H; Liu Y; Zhou X; Zhu H; Zhang S
Front Endocrinol (Lausanne); 2022; 13():877341. PubMed ID: 35721724
[TBL] [Abstract][Full Text] [Related]
17. Coronary artery myointimal dysplasia in patients with pheochromocytoma-possible causal relationship: pathophysiology and clinical implication with reference to Takotsubo cardiomyopathy and spontaneous coronary dissection.
Chow LTC; Chow MBCY
Cardiovasc Pathol; 2018; 37():45-53. PubMed ID: 30342321
[TBL] [Abstract][Full Text] [Related]
18. The Role for Metyrosine in the Treatment of Patients With Pheochromocytoma and Paraganglioma.
Gruber LM; Jasim S; Ducharme-Smith A; Weingarten T; Young WF; Bancos I
J Clin Endocrinol Metab; 2021 May; 106(6):e2393-e2401. PubMed ID: 33693908
[TBL] [Abstract][Full Text] [Related]
19. Pathophysiology and Management of Glycemic Alterations before and after Surgery for Pheochromocytoma and Paraganglioma.
Lopez C; Bima C; Bollati M; Bioletto F; Procopio M; Arata S; Candela DG; Beccuti G; Ghigo E; Maccario M; Parasiliti-Caprino M
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982228
[TBL] [Abstract][Full Text] [Related]
20. Surgical strategies of complicated pheochromocytomas/paragangliomas and literature review.
Wang X; Zhao Y; Liao Z; Zhang Y
Front Endocrinol (Lausanne); 2023; 14():1129622. PubMed ID: 37152961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
